ALX Oncology Holdings Inc. (NASDAQ:ALXO) Director Rekha Hemrajani Buys 30,000 Shares

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Director Rekha Hemrajani purchased 30,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were purchased at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the purchase, the director now directly owns 33,000 shares in the company, valued at $51,150. The trade was a 1,000.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ALX Oncology Price Performance

ALXO traded up $0.02 during trading on Wednesday, reaching $1.57. 1,118,851 shares of the stock were exchanged, compared to its average volume of 785,839. The business’s 50 day moving average price is $1.52 and its two-hundred day moving average price is $4.19. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The company has a market capitalization of $82.54 million, a price-to-earnings ratio of -0.52 and a beta of 1.04. ALX Oncology Holdings Inc. has a 1 year low of $1.19 and a 1 year high of $17.83.

Institutional Trading of ALX Oncology

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of ALX Oncology by 4.3% in the first quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock worth $17,466,000 after acquiring an additional 64,055 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of ALX Oncology by 423.0% in the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after acquiring an additional 514,133 shares during the last quarter. Privium Fund Management B.V. raised its holdings in shares of ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock worth $926,000 after acquiring an additional 112,093 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of ALX Oncology by 87.2% in the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock worth $2,642,000 after acquiring an additional 204,100 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of ALX Oncology in the third quarter worth $578,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research note on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research note on Tuesday, November 12th. Stifel Nicolaus restated a “hold” rating and issued a $3.00 price target (down from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Finally, UBS Group decreased their price target on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 16th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $12.50.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.